



Dr. Peter Rahfeld

Dr. Peter Rahfeld is a renowned protein biochemist specializing in carbohydrate active enzymes (CAZymes). As the Chief Scientific Officer of Avivo Biomedical Inc., he is dedicated to utilizing CAZymes for the advancement of human health. He also holds the title of Honorary Research Associate at the University of British Columbia (UBC), Canada. During his time as a postdoctoral fellow at UBC, Dr. Rahfeld was working in the research group of Prof. Stephen Withers to discover blood group ABH antigen cleaving enzymes through extensive screening of the human gut microbiome. The success of this project yielded an enzyme system, which allows specific and effective conversion of A antigens to H antigens on cells and tissues. In 2020, he co-founded the biotech company, Avivo Biomedical Inc. (formerly known as ABOzymes Biomedical Inc.) to bring this scientific discovery to clinical application. Dr. Rahfeld earned his PhD in 2015 from the Max Planck Institute of Chemical Ecology in Jena, Germany, where he worked on the discovery and characterization of enzymes and pathways involved in the catabolism and biosynthesis of carbohydrates and glycosides in various insect organisms.